Lexology February 16, 2024
Reed Smith LLP

Key takeaways

  • HHS and FDA have released regulatory agendas for 2024 and beyond
  • Priorities include rulemaking and guidance documents impacting the pharmacy industry
  • Pharmacies and other industry stakeholders should stay apprised of developments and understand how regulatory activities could impact their businesses

On February 9, 2024, the Department of Health and Human Services (HHS) published its semiannual regulatory agenda identifying the regulatory activities the Department expects to undertake in the foreseeable future. Among the identified activities, the Department notes the Food and Drug Administration’s (FDA) plans to propose rules on the following topics that could impact pharmacies nationwide:

  • Additions to 503A and 503B Bulks Lists. FDA intends to identify and consider additional bulk drug substances to propose...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns
HHS Explores Stronger FDA Oversight for Food Ingredients

Share This Article